[subhed]The addition of durvalumab plus tremelimumab to standard-of-care chemotherapy did not improve survival or overall response rate (ORR) among patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC), according to results of a phase 2 trial presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020. [/subhead]
“Further studies to assess biomarkers that may predict immune sensitivity in this setting are underway and we hope to have this data to present at upcoming conferences,” Daniel Renouf, MD, MPH, FRCPC, of the University of British Columbia in Canada, and presenter of the study, said. Read more . . .